India's Drug Regulator Flags 159 Samples as Not of Standard Quality in May
Auf einen Blick
- India's Central Drugs Standard Control Organisation (CDSCO) identified 159 drug samples as not of standard quality (NSQ) in May, with 113 flagged by state labs and 46 by central labs.
- One spurious drug sample was also found in Assam.
- CDSCO noted these findings apply only to specific batches.
KI-generierte Zusammenfassung
Warum es wichtig ist
India's drug regulator conducts routine surveillance to ensure the quality of pharmaceutical products. Findings of non-standard quality drugs can lead to regulatory actions and impact public health.
Representative image
NEW DELHI: India's drug regulator flagged 159 drug samples as not of standard quality (NSQ) during routine surveillance in May, while identifying one spurious drug sample in Assam, according to the latest monthly alert issued by Central Drugs Standard Control Organisation (CDSCO).
Of the total, 46 samples were declared NSQ by central drug labs and 113 by state drug labs.
Drugs are listed as NSQ when they fail prescribed quality parameters.
CDSCO clarified that the findings relate only to specific batches and do not imply that other batches of the same products are substandard. TNN
Offene Fragen
- What specific quality parameters were not met?
- What actions will be taken against the manufacturers of NSQ drugs?
